-
Product Insights
New![]()
Net Present Value Model: Zentalis Pharmaceuticals Inc’s Azenosertib
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Zentalis Pharmaceuticals Inc's Azenosertib Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed or refractory osteosarcoma, epithelial ovarian carcinoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Refractory Acute Myeloid Leukemia Drug Details: Azenosertib (ZNC-3) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Relapsed Acute Myeloid Leukemia Drug Details: Azenosertib (ZNC-3) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Secondary Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Secondary Acute Myeloid Leukemia Drug Details: Azenosertib (ZNC-3) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab duocarmazine in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab duocarmazine in Ovarian Cancer Drug Details: Trastuzumab duocarmazine (SYD-985) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Solid Tumor Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Ovarian Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Uterine Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Uterine Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Epithelial Ovarian Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Fallopian Tube Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Fallopian Tube Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Osteosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Osteosarcoma Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Peritoneal Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Metastatic Colorectal Cancer Drug Details: Azenosertib (ZNC-3) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab duocarmazine in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab duocarmazine in Endometrial Cancer Drug Details: Trastuzumab duocarmazine (SYD-985) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab duocarmazine in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab duocarmazine in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Osteosarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in OsteosarcomaDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Ovarian CancerDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Fallopian Tube Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Fallopian Tube CancerDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Solid TumorDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Peritoneal CancerDrug Details:Azenosertib (ZNC-3) is under development for the treatment solid tumors including relapsed...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.